CCNF
Basic information
Region (hg38): 16:2429394-2458854
Links
Phenotypes
GenCC
Source:
- amyotrophic lateral sclerosis (Supportive), mode of inheritance: AD
- amyotrophic lateral sclerosis (Limited), mode of inheritance: AD
- frontotemporal dementia and/or amyotrophic lateral sclerosis 5 (Limited), mode of inheritance: AD
- frontotemporal dementia and/or amyotrophic lateral sclerosis 5 (Strong), mode of inheritance: AD
Clinical Genomic Database
Source:
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
|---|---|---|---|---|---|
| Frontotemporal dementia and/or amyotrophic lateral sclerosis 5 | AD | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Neurologic | 27080313 |
ClinVar
This is a list of variants' phenotypes submitted to
- not_specified (80 variants)
- not_provided (50 variants)
- CCNF-related_disorder (12 variants)
- Frontotemporal_dementia_and/or_amyotrophic_lateral_sclerosis_5 (11 variants)
- Amyotrophic_lateral_sclerosis (2 variants)
- Frontotemporal_dementia (1 variants)
- Polyneuropathy (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CCNF gene is commonly pathogenic or not. These statistics are base on transcript: NM_000001761.3. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 19 | 22 | ||||
| missense | 91 | 14 | 113 | |||
| nonsense | 1 | |||||
| start loss | 0 | |||||
| frameshift | 1 | |||||
| splice donor/acceptor (+/-2bp) | 0 | |||||
| Total | 2 | 1 | 93 | 33 | 8 |
Highest pathogenic variant AF is 0.0000343805
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| CCNF | protein_coding | protein_coding | ENST00000397066 | 17 | 29461 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 0.127 | 0.873 | 125729 | 0 | 19 | 125748 | 0.0000756 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | 0.741 | 424 | 469 | 0.904 | 0.0000286 | 5084 |
| Missense in Polyphen | 101 | 144.6 | 0.69847 | 1540 | ||
| Synonymous | 0.433 | 203 | 211 | 0.962 | 0.0000142 | 1572 |
| Loss of Function | 4.44 | 10 | 40.5 | 0.247 | 0.00000222 | 427 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.000119 | 0.000119 |
| Ashkenazi Jewish | 0.00 | 0.00 |
| East Asian | 0.000163 | 0.000163 |
| Finnish | 0.00 | 0.00 |
| European (Non-Finnish) | 0.0000892 | 0.0000879 |
| Middle Eastern | 0.000163 | 0.000163 |
| South Asian | 0.0000993 | 0.0000980 |
| Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Substrate recognition component of a SCF (SKP1-CUL1-F- box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of CP110 during G2 phase, thereby acting as an inhibitor of centrosome reduplication. {ECO:0000269|PubMed:20596027}.;
- Pathway
- Post-translational protein modification;Metabolism of proteins;Immune System;Adaptive Immune System;Antigen processing: Ubiquitination & Proteasome degradation;Class I MHC mediated antigen processing & presentation;Neddylation
(Consensus)
Recessive Scores
- pRec
- 0.131
Intolerance Scores
- loftool
- 0.488
- rvis_EVS
- -1.22
- rvis_percentile_EVS
- 5.67
Haploinsufficiency Scores
- pHI
- 0.572
- hipred
- Y
- hipred_score
- 0.712
- ghis
- 0.673
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.869
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Ccnf
- Phenotype
- cellular phenotype; growth/size/body region phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); limbs/digits/tail phenotype; embryo phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan);
Gene ontology
- Biological process
- regulation of cyclin-dependent protein serine/threonine kinase activity;protein polyubiquitination;mitotic cell cycle;re-entry into mitotic cell cycle;placenta development;protein phosphorylation;regulation of mitotic nuclear division;positive regulation of cell population proliferation;negative regulation of centrosome duplication;protein ubiquitination;SCF-dependent proteasomal ubiquitin-dependent protein catabolic process;post-translational protein modification;positive regulation of cell cycle;cell division
- Cellular component
- cyclin-dependent protein kinase holoenzyme complex;nucleus;cytoplasm;centrosome;centriole;cytosol;SCF ubiquitin ligase complex;cell junction
- Molecular function
- protein kinase activity;ubiquitin-protein transferase activity;protein binding;cyclin-dependent protein serine/threonine kinase regulator activity;protein kinase binding